{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T08:51:33Z","timestamp":1773564693021,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.bcp.2009.01.001","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T09:10:48Z","timestamp":1232097048000},"page":"1236-1245","source":"Crossref","is-referenced-by-count":28,"title":["Suramin inhibits the CD40\u2013CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects"],"prefix":"10.1016","volume":"77","author":[{"given":"Emilio","family":"Margolles-Clark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Caroline","family":"Jacques-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Umland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma S.","family":"Kenyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Ricordi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Olof","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Buchwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2009.01.001_bib1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1600-6143.2006.01259.x","article-title":"A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression","volume":"6","author":"Larsen","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bcp.2009.01.001_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.med.58.080205.154004","article-title":"T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation","volume":"58","author":"Vincenti","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bcp.2009.01.001_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.1996.tb00921.x","article-title":"The role of CD40 ligand in costimulation and T-cell activation","volume":"153","author":"Grewal","year":"1996","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bcp.2009.01.001_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Sch\u00f6nbeck","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bcp.2009.01.001_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bcp.2009.01.001_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.22.012703.104533","article-title":"CD40\/CD154 interactions at the interface of tolerance and immunity","volume":"22","author":"Quezada","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bcp.2009.01.001_bib7","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.96.14.8132","article-title":"Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154","volume":"96","author":"Kenyon","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2009.01.001_bib8","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.2337\/db05-1673","article-title":"CD40\u2013CD40 ligand interaction activates proinflammatory pathways in pancreatic islets","volume":"55","author":"Barb\u00e9-Tuana","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2009.01.001_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0031-6997(24)01373-5","article-title":"Receptors for purines and pyrimidines","volume":"50","author":"Ralevic","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2009.01.001_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0031-6997(25)00445-4","article-title":"Recent research on the biological activity of suramin","volume":"45","author":"Voogd","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2009.01.001_bib11","first-page":"2239","article-title":"Suramin: a novel antineoplastic agent with multiple potential mechanisms of action","volume":"53","author":"Stein","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.01.001_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.1987.03400100081025","article-title":"Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group","volume":"258","author":"Cheson","year":"1987","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bcp.2009.01.001_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1015666024386","article-title":"Suramin's development: what did we learn?","volume":"20","author":"Kaur","year":"2002","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bcp.2009.01.001_bib14","first-page":"90","article-title":"Postoperative complications in patients receiving suramin therapy","volume":"116","author":"Cole","year":"1994","journal-title":"Surgery"},{"key":"10.1016\/j.bcp.2009.01.001_bib15","first-page":"4694","article-title":"Antiproliferative effects of suramin on lymphoid cells","volume":"47","author":"Spigelman","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.01.001_bib16","first-page":"3036","article-title":"Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression","volume":"50","author":"Mills","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.01.001_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000236452","article-title":"Suramin affects human peripheral blood mononuclear cells in vitro: inhibition of T cell growth and modulation of cytokine secretion","volume":"101","author":"Czernin","year":"1993","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.bcp.2009.01.001_bib18","first-page":"598","article-title":"Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties","volume":"81","author":"Schiller","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2009.01.001_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF00918142","article-title":"Suramin inhibits the mixed lymphocyte reaction by suppressing lymphokine production","volume":"12","author":"Shenoy","year":"1992","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.bcp.2009.01.001_bib20","unstructured":"Zheng Z, Carter MB, Liao Y, Sun L, Kirkovsky L, Mrose S, et al., inventors; Biogen, Inc., assignee. Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications. US patent 7,173,046 B2. 2007 [February 6, 2007]."},{"key":"10.1016\/j.bcp.2009.01.001_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2184.1999.3240203.x","article-title":"Optimized fluorescent probe combinations for evaluation of proliferation and necrosis in anthracycline-treated leukaemic cell lines","volume":"32","author":"Boutonnat","year":"1999","journal-title":"Cell Prolif"},{"key":"10.1016\/j.bcp.2009.01.001_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-1759(03)00009-7","article-title":"A simple method for detecting up to five immunofluorescent parameters together with DNA staining for cell cycle or viability on a benchtop flow cytometer","volume":"275","author":"Gordon","year":"2003","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bcp.2009.01.001_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2337\/diab.37.4.413","article-title":"Automated method for isolation of human pancreatic islets","volume":"37","author":"Ricordi","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2009.01.001_bib24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0006-2952(99)00150-1","article-title":"Inhibition of tumor necrosis factor-alpha (TNF-alpha)\/TNF-alpha receptor binding by structural analogues of suramin","volume":"58","author":"Mancini","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2009.01.001_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im0309s57","article-title":"Early events in B lymphocyte activation","author":"Bondada","year":"2003","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.bcp.2009.01.001_bib26","doi-asserted-by":"crossref","first-page":"24603","DOI":"10.1074\/jbc.273.38.24603","article-title":"Detailed comparison of two molecular models of the human CD40 ligand with an X-ray structure and critical assessment of model-based mutagenesis and residue mapping studies","volume":"273","author":"Bajorath","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.01.001_bib27","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1016\/S0021-9258(18)31420-0","article-title":"Suramin induces deoligomerization of human tumor necrosis factor \u03b1","volume":"268","author":"Alzani","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.01.001_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nchembio746","article-title":"C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L","volume":"1","author":"Fournel","year":"2005","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bcp.2009.01.001_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1399-3011.2005.00256.x","article-title":"Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade","volume":"65","author":"Allen","year":"2005","journal-title":"J Pept Res"},{"key":"10.1016\/j.bcp.2009.01.001_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00109-008-0416-1","article-title":"Inhibition of CD40\u2013CD154 costimulatory pathway by a cyclic peptide targeting CD154","volume":"87","author":"Deambrosis","year":"2009","journal-title":"J Mol Med"},{"key":"10.1016\/j.bcp.2009.01.001_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/s10165-005-0442-6","article-title":"Identification of three novel peptides that inhibit CD40\u2013CD154 interaction","volume":"15","author":"Kitagawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.bcp.2009.01.001_bib32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","article-title":"Requirement for CD154 in the progression of atherosclerosis","volume":"5","author":"Lutgens","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2009.01.001_bib33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1345\/aph.1D611","article-title":"CD40 ligand: a novel target in the fight against cardiovascular disease","volume":"38","author":"Vishnevetsky","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bcp.2009.01.001_bib34","doi-asserted-by":"crossref","first-page":"18307","DOI":"10.1074\/jbc.M700211200","article-title":"CD40-40L signaling in vascular inflammation","volume":"282","author":"Chakrabarti","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.01.001_bib35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/gut.2006.111989","article-title":"Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease","volume":"56","author":"Danese","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2009.01.001_bib36","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.106.683201","article-title":"CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1","volume":"115","author":"Zirlik","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2009.01.001_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cyto.2005.11.012","article-title":"Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-\u03baB activity","volume":"33","author":"Goto","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.bcp.2009.01.001_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0008-8749(85)90135-2","article-title":"Effects of suramin on the immune responses to sheep red blood cells in mice. II. In vitro studies","volume":"93","author":"Motta","year":"1985","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bcp.2009.01.001_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1253\/circj.66.385","article-title":"Suppression of myocardial inflammation using suramin, a growth factor blocker","volume":"66","author":"Shiono","year":"2002","journal-title":"Circ J"},{"key":"10.1016\/j.bcp.2009.01.001_bib40","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1200\/JCO.2001.19.13.3260","article-title":"Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas","volume":"19","author":"Grossman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2009.01.001_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nm1049","article-title":"Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice","volume":"10","author":"Eichhorst","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2009.01.001_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-6147(99)01337-1","article-title":"G protein antagonists","volume":"20","author":"Freissmuth","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.01.001_bib43","doi-asserted-by":"crossref","first-page":"12281","DOI":"10.1074\/jbc.273.20.12281","article-title":"Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases","volume":"273","author":"Zhang","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.01.001_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/jpet.104.078311","article-title":"Suramin disrupts receptor-G protein coupling by blocking association of G protein \u03b1 and \u03b2\u03b3 subunits","volume":"313","author":"Chung","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.01.001_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.intimp.2003.09.004","article-title":"Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo","volume":"4","author":"Denkinger","year":"2004","journal-title":"Int Immunopharmacol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:16:58Z","timestamp":1738887418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0006295209000021"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.01.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}